A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation.

Drugs · 2023 · PMC10015535 · PMID 36920652

Europe PMC DOI

hedged sentence

0.0005

closest p · 0.0× alpha

0.0005

boldest claim

The sentences

highly significantp < 0.0005actually significant

Survival improvement in favor of pretreatment with one dose of 10 mg/kg RRx-001 over vehicle control in irradiated mice was highly significant ( p < 0.0005), with an approximate 33.4% reduction in the 30-day death risk [ 65 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.